- Home
- ZYME vs SAFE Comparison
ZYME vs SAFE Comparison
Compare ZYME & SAFE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZYME
- SAFE
- Stock Information
- Founded
- ZYME 2003
- SAFE 2016
- Country
- ZYME United States
- SAFE United States
- Employees
- ZYME N/A
- SAFE N/A
- Industry
- ZYME Biotechnology: Pharmaceutical Preparations
- SAFE Real Estate Investment Trusts
- Sector
- ZYME Health Care
- SAFE Real Estate
- Exchange
- ZYME Nasdaq
- SAFE Nasdaq
- Market Cap
- ZYME 1.2B
- SAFE 1.2B
- IPO Year
- ZYME 2017
- SAFE 2017
- Fundamental
- Price
- ZYME $16.46
- SAFE $13.24
- Analyst Decision
- ZYME Strong Buy
- SAFE Buy
- Analyst Count
- ZYME 7
- SAFE 9
- Target Price
- ZYME $22.00
- SAFE $19.56
- AVG Volume (30 Days)
- ZYME 889.7K
- SAFE 393.5K
- Earning Date
- ZYME 11-06-2025
- SAFE 11-05-2025
- Dividend Yield
- ZYME N/A
- SAFE 5.34%
- EPS Growth
- ZYME N/A
- SAFE N/A
- EPS
- ZYME N/A
- SAFE 1.57
- Revenue
- ZYME $134,481,000.00
- SAFE $398,968,000.00
- Revenue This Year
- ZYME $99.52
- SAFE $0.58
- Revenue Next Year
- ZYME N/A
- SAFE $4.98
- P/E Ratio
- ZYME N/A
- SAFE $8.44
- Revenue Growth
- ZYME 116.21
- SAFE N/A
- 52 Week Low
- ZYME $9.03
- SAFE $12.83
- 52 Week High
- ZYME $19.98
- SAFE $21.90
- Technical
- Relative Strength Index (RSI)
- ZYME 36.30
- SAFE 29.66
- Support Level
- ZYME $17.27
- SAFE $12.87
- Resistance Level
- ZYME $19.98
- SAFE $14.71
- Average True Range (ATR)
- ZYME 0.76
- SAFE 0.54
- MACD
- ZYME -0.27
- SAFE -0.21
- Stochastic Oscillator
- ZYME 11.48
- SAFE 12.43
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
About SAFE Safehold Inc. New
Safehold Inc is a REIT that operates its business by acquiring, managing, and capitalizing ground leases. Ground leases are long-term contracts between the landlord (the Company) and a tenant or leaseholder. Ground leases generally represent ownership of the land underlying commercial real estate projects that are net leased by the fee owner of the land to the owners/operators of the real estate projects built thereon.